MM-121 (SAR256212), an Anti-ErbB3 Monoclonal Antibody, Shows Synergistic Tumor Growth Inhibition in Combination with a Pan-PI3K Inhibitor or a Microtubule Inhibitor Through ErbB3 Expression Modulation

被引:2
作者
Henry, C. [1 ]
Geslin, C. [1 ]
Blanchet, A. M. [1 ]
Nicolazzi, C. [1 ]
Garcia, G. [2 ]
Vincent, L. [1 ]
Blanc, V. [1 ]
Tabah-Fisch, I. [1 ]
Chiron, M. [1 ]
机构
[1] Sanofi R&D, Oncol, Vitry Sur Seine, France
[2] Merrimack Pharmaceut, Cambridge, MA USA
关键词
D O I
10.1016/S0959-8049(12)72123-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
325
引用
收藏
页码:99 / 99
页数:1
相关论文
共 2 条
[1]   Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors [J].
Chakrabarty, Anindita ;
Sanchez, Violeta ;
Kuba, Maria G. ;
Rinehart, Cammie ;
Arteaga, Carlos L. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (08) :2718-2723
[2]   Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin [J].
Wang, S. ;
Huang, X. ;
Lee, C-K ;
Liu, B. .
ONCOGENE, 2010, 29 (29) :4225-4236